CD Capital led a USD50m Series A for Neukio Biotherapeutics, a China-based developer of cell therapies for cancer treatment, with participation from Alwin Capital and Surplus Capital, and follow-on from Lilly Asia Ventures, Sherpa Healthcare Partners and IDG Capital. Read more here and here